1. Home
  2. ATNM vs GRF Comparison

ATNM vs GRF Comparison

Compare ATNM & GRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.36

Market Cap

47.1M

Sector

Health Care

ML Signal

HOLD

Logo Eagle Capital Growth Fund Inc.

GRF

Eagle Capital Growth Fund Inc.

HOLD

Current Price

$10.70

Market Cap

42.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNM
GRF
Founded
2000
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
47.1M
42.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ATNM
GRF
Price
$1.36
$10.70
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
182.4K
3.0K
Earning Date
11-14-2025
01-01-0001
Dividend Yield
N/A
3.70%
EPS Growth
N/A
N/A
EPS
N/A
1.16
Revenue
$90,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.15
Revenue Growth
11.11
N/A
52 Week Low
$1.03
$7.93
52 Week High
$2.41
$10.19

Technical Indicators

Market Signals
Indicator
ATNM
GRF
Relative Strength Index (RSI) 41.07 50.40
Support Level $1.57 $10.61
Resistance Level $1.72 $11.58
Average True Range (ATR) 0.10 0.38
MACD -0.03 -0.01
Stochastic Oscillator 0.00 28.57

Price Performance

Historical Comparison
ATNM
GRF

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About GRF Eagle Capital Growth Fund Inc.

Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.

Share on Social Networks: